Mechanism and therapeutic implications of pomalidomide-induced immune surface marker upregulation in EBV-positive lymphomas
Abstract Epstein-Barr virus (EBV) downregulates immune surface markers to avoid immune recognition. Pomalidomide (Pom) was previously shown to increase immune surface marker expression in EBV-infected tumor cells. We explored the mechanism by which Pom leads to these effects in EBV-infected cells. P...
Main Authors: | Hannah K. Jaeger, David A. Davis, Ashwin Nair, Prabha Shrestha, Alexandra Stream, Amulya Yaparla, Robert Yarchoan |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2023-07-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-023-38156-z |
Similar Items
-
Pomalidomide restores immune recognition of primary effusion lymphoma through upregulation of ICAM-1 and B7-2.
by: Prabha Shrestha, et al.
Published: (2021-01-01) -
Pomalidomide increases immune surface marker expression and immune recognition of oncovirus-infected cells
by: David A. Davis, et al.
Published: (2019-02-01) -
Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin’s lymphoma
by: Hao-Wei Wang, et al.
Published: (2021-02-01) -
Regulation of the Dimerization and Activity of SARS-CoV-2 Main Protease through Reversible Glutathionylation of Cysteine 300
by: David A. Davis, et al.
Published: (2021-08-01) -
EBV & lymphoma
by: Dolores Caballero, (Coordinating Author)
Published: (2019-06-01)